Remove 2029 Remove Diabetes Remove Pharmaceutical Companies
article thumbnail

New US fill finish facility receives $4.1 billion investment

European Pharmaceutical Review

[the new facility will double] the combined square footage of all three of [Novo Nordisk]’s existing facilities in North Carolina” Overall, the expansion will support Novo Nordisk’s ability to produce injectable treatments for obesity and other chronic diseases such as diabetes. This is compared to the company’s $3.9 (DKK

Diabetes 104
article thumbnail

T2D market growth driven by novel GLP-1RAs and once-weekly basal insulin therapies

Pharmaceutical Technology

Type 2 diabetes (T2D) is a crowded and competitive landscape with multiple “me-too,” generic and biosimilar drugs entering the market, with market growth primarily driven by an increasing prevalent population across nine major markets (9MM: US, France, Germany, Italy, Spain, UK, Japan, China, and India).